Literature DB >> 8100571

CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents.

S Muto1, V Vĕtvicka, G D Ross.   

Abstract

CR3 (CD11b/CD18) functions both as an iC3b-receptor and as an adhesion molecule for cellular ligands such as ICAM-1. Although CR3 has been well characterized on phagocytic cells, much less is known about CR3 on lymphocytes. In this study, the expression of CR3 was examined on resting and stimulated B, T, and natural killer (NK) cells by three-color flow cytometry. Biotinylated anti-CR3 mAb and streptavidin-FITC were used in combination with anti-CD3 mAb conjugated with peridinin chlorophyll-alpha protein (PerCP) and phycoerythrin-labeled mAbs to CD4, CD8, CD19, or CD56. Among resting lymphocytes, CR3 was expressed on nearly all NK cells (CD56+CD3-), 1% of CD4+CD3+ helper T cells, 7% of CD8+CD3+ cytotoxic T cells, and 20% of B cells (CD19+). Among the 5% of T cells (CD3+) expressing CR3, the majority was CD56+. Incubation of PBMC for 30 min with PMA induced a three- to fivefold increase in CR3 expression on NK cells and a twofold increase on T cells but did not change the expression of CR3 on B cells. This effect of PMA was not blocked by the presence of cycloheximide, suggesting the presence of cytoplasmic (granule) stores of CR3 in these lymphoid cells resembling those previously reported in neutrophils and monocytes. When PBMC were incubated with rIFN-alpha, rIL-2, beta-glucan, or high concentrations of LPS, expression of CR3 on NK cells increased significantly, but > or = 4 hr of stimulation was required. Other cytokines (rIFN-gamma, rIL-1, rIL-4, rIL-6, TNF-alpha) and rC5a had no significant effect on CR3 expression. Among NK cells, both the CD56bright and the CD56dim cells expressed CR3, and the expression of CR3 on both of these NK cell subsets was increased in a similar manner by PMA. However, rIL-2 stimulated a greater increase in CR3 expression on CD56bright cells than on CD56dim cells. These studies suggest that CR3 expressed by NK cells or cytotoxic T cells resembles phagocyte CR3 in that cellular activation stimulates increased surface expression of CR3 derived from cytoplasmic reserves of the receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100571     DOI: 10.1007/bf00919970

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

1.  Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface.

Authors:  L J Miller; D F Bainton; N Borregaard; T A Springer
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

2.  Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation.

Authors:  L J Miller; R Schwarting; T A Springer
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

3.  Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3.

Authors:  B L Myones; J G Dalzell; N Hogg; G D Ross
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

4.  Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b.

Authors:  G D Ross; J A Cain; P J Lachmann
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  Lipopolysaccharide-induced stimulation of CD11b/CD18 expression on neutrophils. Evidence of specific receptor-based response and inhibition by lipid A-based antagonists.

Authors:  W A Lynn; C R Raetz; N Qureshi; D T Golenbock
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

6.  Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells.

Authors:  K A Ault; T A Springer
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

7.  Modulation of adhesion molecules on human large granular lymphocytes by interleukin-2 in vivo and in vitro.

Authors:  P L Triozzi; D M Eicher; J J Rinehart
Journal:  Cell Immunol       Date:  1992-04       Impact factor: 4.868

8.  Human C5a modulates monocyte Fc and C3 receptor expression.

Authors:  K B Yancey; J O'Shea; T Chused; E Brown; T Takahashi; M M Frank; T J Lawley
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

9.  Co-expression of Mac-1 and p150,95 on CD5+ B cells. Structural and functional characterization in a human chronic lymphocytic leukemia.

Authors:  A De la Hera; M Alvarez-Mon; F Sanchez-Madrid; C Martinez; A Durantez
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

10.  Bacterial activation of human natural killer cells: role of cell surface lipopolysaccharide.

Authors:  R A Lindemann
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

View more
  14 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials.

Authors:  Catarina R Almeida; Daniela P Vasconcelos; Raquel M Gonçalves; Mário A Barbosa
Journal:  J R Soc Interface       Date:  2011-07-13       Impact factor: 4.118

3.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

4.  Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration.

Authors:  Dafeng Chu; Xinyue Dong; Qi Zhao; Jingkai Gu; Zhenjia Wang
Journal:  Adv Mater       Date:  2017-05-15       Impact factor: 30.849

5.  Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Authors:  Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

Review 6.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice.

Authors:  Souad Rahmouni; Einar Martin Aandahl; Btissam Nayjib; Mustapha Zeddou; Sandra Giannini; Myriam Verlaet; Roland Greimers; Jaques Boniver; Kjetil Tasken; Michel Moutschen
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

8.  T lymphocytes in acute bacterial infection: increased prevalence of CD11b(+) cells in the peripheral blood and recruitment to the infected site.

Authors:  Christof Wagner; Dimitra Kotsougiani; Marco Pioch; Birgit Prior; Andreas Wentzensen; Gertrud Maria Hänsch
Journal:  Immunology       Date:  2008-05-13       Impact factor: 7.397

9.  Leukocyte integrin Mac-1 promotes acute cardiac allograft rejection.

Authors:  Koichi Shimizu; Peter Libby; Rica Shubiki; Masashi Sakuma; Yunmei Wang; Kenichi Asano; Richard N Mitchell; Daniel I Simon
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

10.  Blocking of integrins inhibits HIV-1 infection of human cervical mucosa immune cells with free and complement-opsonized virions.

Authors:  Veronica Tjomsland; Rada Ellegård; Preben Kjölhede; Ninni Borendal Wodlin; Jorma Hinkula; Jeffrey D Lifson; Marie Larsson
Journal:  Eur J Immunol       Date:  2013-06-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.